FDA | What's New
Follow
FDA grants accelerated approval to sacituzumab govitecan for advanced urothelial cancer
FDA granted accelerated approval to sacituzumab govitecan (Trodelvy, Immunomedics Inc.) for patients with locally advanced or metastatic urothelial cancer who previously received a platinum-containing chemotherapy and either a PD-1 or PD-L1 inhibitor.
